首页> 外文OA文献 >Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Post-Void Residual Volume or Urinary Retention Risk

【2h】

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Post-Void Residual Volume or Urinary Retention Risk

机译：将米拉贝隆添加到索非那新中以治疗膀胱过度活动症对无效后残留量或尿Re留风险几乎没有影响

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

[no abstract]

机译：[没有摘要]

著录项

作者
Drake MJ; MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Herschorn S; Huang M; Stoelzel M; Siddiqui E;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献
专利

1. Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk [J] . Marcus J. Drake, Scott MacDiarmid, Salman Al-Shukri, Urology . 2017,第期

机译：将m拉萨克顿添加到索尔替芬蛋白，以治疗过度活跃的膀胱对后瓣残留体积或尿潴留风险影响不大
2. POST-VOID RESIDUAL (PVR) VOLUME AND URINARY RETENTION ASSESSMENTS IN A RANDOMIZED, DOUBLE-BLIND, PHASE IIIB TRIAL OF MIRABEGRON ADD-ON TREATMENT IN INCONTINENT OVERACTIVE BLADDER (OAB) PATIENTS WITH AN INADEQUATE RESPONSE TO 4-WEEK SOLIFENACIN MONOTHERAPY (BESIDE) [J] . Drake M., MacDiarmid S., Al-Shukri S., Neurourology and urodynamics. . 2016,第Suppla4期

机译：在无反应性膀胱过度活动性（OAB）患者中，对4周未完成反应的随机，双盲，IIIB期随机，双盲，IIIB期试验中的残留残留量（PVR）和尿液保留评估
3. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study) [J] . Yamaguchi Osamu, Kakizaki Hidehiro, Homma Yukio, BJU international . 2015,第4期

机译：米拉贝隆在索非那新治疗的膀胱过度活动症患者中作为“附加”疗法的安全性和有效性：日本的一项上市后开放标签研究（MILAI研究）
4. Electrical stimulation of the saphenous nerve in anesthetized rats: A novel therapeutic approach to treating overactive bladder [C] . Zainab Moazzam, Paul B. Yoo Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：麻醉大鼠隐神经的电刺激：一种治疗膀胱过度活动症的新治疗方法
5. Calcium(II)-activated potassium(I) channels in urinary bladder smooth muscle: Functional role and potential as therapeutic targets for overactive bladder. [D] . Soder, Rupal Pandey. 2012

机译：膀胱平滑肌中的钙（II）活化钾（I）通道：功能作用和潜力作为膀胱过度活动症的治疗靶标。
6. Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder [O] . Yankai Xu, Ruihua Liu, Chu Liu, 2017

机译：Mirabegron联合索非那新治疗膀胱过度活动症的疗效和安全性的Meta分析
7. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study) [O] . Osamu Yamaguchi, Hidehiro Kakizaki, Yukio Homma, 2015

机译：Mirabegron的安全性和疗效作为索尔替尼蛋白治疗过度活性膀胱患者的“加载项”治疗：日本营销后，开放标签研究（Milai学习）

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Post-Void Residual Volume or Urinary Retention Risk

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅